Mechanisms of Resistance Exercise Training for Improved Muscle Insulin Sensitivity

NCT07128368 | Not Yet Recruiting

• 2 other identifiers: 24-011544K01DK141911
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

To uncover the underlying mechanisms of resistance exercise training benefits on glucose metabolism and insulin sensitivity in muscle.

Conditions

Resistance Training

Outcome Measures

Primary Outcomes (1)

• Change in muscle protein synthesis

  Rate of insulin-stimulated synthesis of individual proteins

  Baseline; 8 weeks

Study Arms (1)

Resistance Exercise Training

EXPERIMENTAL

Other: Resistance Exercise Training

Interventions

Resistance Exercise Training OTHER

Participants will undergo resistance exercise training 3 days a week for approximately 1 hour each day for 8 weeks.

Resistance Exercise Training

Eligibility Criteria

• Age: 30 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Sedentary (≤30min of physical activity on ≤1 day/week)
• Weight stable for ≥3 months prior to study

You may not qualify if:

• Active coronary artery disease or heart failure.
• Participation in a structured exercise program \> 1 day/week.
• A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
• Abnormal liver function test results (Transaminase \>2 times the upper limit of normal)
• Abnormal renal function test results (calculated GFR \<60 mL/min/1.73m2); If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
• Uncontrolled thyroid disease (TSH undetectable or \>10 mlU/L); testing required within three months prior to admission for subjects with a goiter, positive antibodies, or who are on thyroid hormone replacement, and within one year otherwise
• Abuse of alcohol or recreational drugs
• Active tobacco usage
• Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis).
• Uncontrolled arterial hypertension (Resting diastolic blood pressure \>90 mmHg and/or systolic blood pressure \>160 mmHg) at the time of screening.
• A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol
• Active pregnancy
• Menopause (defined as absence of menstruation for 12 consecutive months)
• Restrictions on Use of Other Drugs or Treatments:
• Any other medication believed to be a contraindication to the subject's participation.

Sponsors & Collaborators

• Mayo Clinic: lead
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): collaborator

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Interventions

Resistance Training

Intervention Hierarchy (Ancestors)

Exercise Therapy; Rehabilitation; Aftercare; Continuity of Patient Care; Patient Care; Therapeutics; Physical Therapy Modalities; Physical Conditioning, Human; Exercise; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Officials

• Mark Pataky

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Consultant I Endocrinology, Diabetes and Metabolism

Study Record Dates

• First Submitted: August 13, 2025
• First Posted: August 18, 2025
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): October 31, 2028
• Last Updated: December 12, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)